Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;80(1-2):17–24. doi: 10.1038/sj.bjc.6690315

A comparative study of the effects of genistein and 2-methoxyestradiol on the proteolytic balance and tumour cell proliferation

I Fajardo 1, A R Quesada 1, I Núñez de Castro 1, F Sánchez-Jiménez 1, M Á Medina 1
PMCID: PMC2363013  PMID: 10389972

Abstract

The cytotoxicity of two compounds described as anti-angiogenic, the isoflavone genistein and the oestrogen metabolite 2-methoxyestradiol, has been studied in different human tumour cell lines. Since the degradation of the extracellular matrix is one of the essential steps in angiogenesis, the potential modulatory effects of both compounds on the proteolytic balance in media conditioned by different human tumour cells have been also investigated. The IC50 values for 2-methoxyestradiol were lower than those for genistein on all the cell lines tested. In all the cell lines expressing measurable amounts of active enzymes, genistein induced a shift towards antiproteolysis in both matrix metalloproteinase/tissue inhibitor of metalloproteinase and urokinase/plasminogen activator inhibitor proteolytic balances. On the other hand, 2-methoxyestradiol did not produce any clear net shift of the proteolytic balance, with the significant exception of the matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in WAC-2 cells, a neuroblastoma cell line with enhanced expression of the N-myc oncogene. © 1999 Cancer Research Campaign

Keywords: angiogenesis, urokinase, plasminogen activator inhibitor, matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase

Full Text

The Full Text of this article is available as a PDF (299.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987 Apr 25;262(12):5592–5595. [PubMed] [Google Scholar]
  2. Alvarez O. A., Carmichael D. F., DeClerck Y. A. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst. 1990 Apr 4;82(7):589–595. doi: 10.1093/jnci/82.7.589. [DOI] [PubMed] [Google Scholar]
  3. Andreasen P. A., Georg B., Lund L. R., Riccio A., Stacey S. N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol. 1990 Jan 2;68(1):1–19. doi: 10.1016/0303-7207(90)90164-4. [DOI] [PubMed] [Google Scholar]
  4. Barnes S., Peterson G., Grubbs C., Setchell K. Potential role of dietary isoflavones in the prevention of cancer. Adv Exp Med Biol. 1994;354:135–147. doi: 10.1007/978-1-4899-0939-8_10. [DOI] [PubMed] [Google Scholar]
  5. Blasi F., Riccio A., Sebastio G. Human plasminogen activators. Genes and proteins structure. Horiz Biochem Biophys. 1986;8:377–414. [PubMed] [Google Scholar]
  6. D'Amato R. J., Lin C. M., Flynn E., Folkman J., Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3964–3968. doi: 10.1073/pnas.91.9.3964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  8. Donaldson K. L., Goolsby G. L., Kiener P. A., Wahl A. F. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ. 1994 Oct;5(10):1041–1050. [PubMed] [Google Scholar]
  9. Dunn J. E. Cancer epidemiology in populations of the United States--with emphasis on Hawaii and California--and Japan. Cancer Res. 1975 Nov;35(11 Pt 2):3240–3245. [PubMed] [Google Scholar]
  10. Emonard H., Grimaud J. A. Matrix metalloproteinases. A review. Cell Mol Biol. 1990;36(2):131–153. [PubMed] [Google Scholar]
  11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995 Jan;1(1):27–31. doi: 10.1038/nm0195-27. [DOI] [PubMed] [Google Scholar]
  12. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 1992 Jun 5;267(16):10931–10934. [PubMed] [Google Scholar]
  13. Fotsis T., Pepper M., Adlercreutz H., Fleischmann G., Hase T., Montesano R., Schweigerer L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2690–2694. doi: 10.1073/pnas.90.7.2690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fotsis T., Zhang Y., Pepper M. S., Adlercreutz H., Montesano R., Nawroth P. P., Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 1994 Mar 17;368(6468):237–239. doi: 10.1038/368237a0. [DOI] [PubMed] [Google Scholar]
  15. Gohji K., Fujimoto N., Fujii A., Komiyama T., Okawa J., Nakajima M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res. 1996 Jul 15;56(14):3196–3198. [PubMed] [Google Scholar]
  16. Gorczyca W., Gong J., Ardelt B., Traganos F., Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 1993 Jul 1;53(13):3186–3192. [PubMed] [Google Scholar]
  17. Holmgren L., O'Reilly M. S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995 Feb;1(2):149–153. doi: 10.1038/nm0295-149. [DOI] [PubMed] [Google Scholar]
  18. Kohn E. C., Liotta L. A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995 May 1;55(9):1856–1862. [PubMed] [Google Scholar]
  19. Lau H. K., Kim M., Koo J., Chiu B., Murray D. Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas. Clin Exp Metastasis. 1995 Nov;13(6):492–498. doi: 10.1007/BF00118188. [DOI] [PubMed] [Google Scholar]
  20. Liotta L. A., Rao C. N., Barsky S. H. Tumor invasion and the extracellular matrix. Lab Invest. 1983 Dec;49(6):636–649. [PubMed] [Google Scholar]
  21. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991 Jan 25;64(2):327–336. doi: 10.1016/0092-8674(91)90642-c. [DOI] [PubMed] [Google Scholar]
  22. Liotta L. A., Tryggvason K., Garbisa S., Hart I., Foltz C. M., Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980 Mar 6;284(5751):67–68. doi: 10.1038/284067a0. [DOI] [PubMed] [Google Scholar]
  23. Messina M. J., Persky V., Setchell K. D., Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 1994;21(2):113–131. doi: 10.1080/01635589409514310. [DOI] [PubMed] [Google Scholar]
  24. Montesano R. 1992 Mack Forster Award Lecture. Review. Regulation of angiogenesis in vitro. Eur J Clin Invest. 1992 Aug;22(8):504–515. doi: 10.1111/j.1365-2362.1992.tb01498.x. [DOI] [PubMed] [Google Scholar]
  25. Nuovo G. J., MacConnell P. B., Simsir A., Valea F., French D. L. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 1995 Jan 15;55(2):267–275. [PubMed] [Google Scholar]
  26. Packman K. S., Demeure M. J., Doffek K. M., Wilson S. D. Increased plasminogen activator and type IV collagenase activity in invasive follicular thyroid carcinoma cells. Surgery. 1995 Dec;118(6):1011–1017. doi: 10.1016/s0039-6060(05)80107-2. [DOI] [PubMed] [Google Scholar]
  27. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  28. Peterson G., Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun. 1991 Aug 30;179(1):661–667. doi: 10.1016/0006-291x(91)91423-a. [DOI] [PubMed] [Google Scholar]
  29. Peterson G., Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 1996 Oct;7(10):1345–1351. [PubMed] [Google Scholar]
  30. Schweigerer L., Breit S., Wenzel A., Tsunamoto K., Ludwig R., Schwab M. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res. 1990 Jul 15;50(14):4411–4416. [PubMed] [Google Scholar]
  31. Schweigerer L., Christeleit K., Fleischmann G., Adlercreutz H., Wähälä K., Hase T., Schwab M., Ludwig R., Fotsis T. Identification in human urine of a natural growth inhibitor for cells derived from solid paediatric tumours. Eur J Clin Invest. 1992 Apr;22(4):260–264. doi: 10.1111/j.1365-2362.1992.tb01460.x. [DOI] [PubMed] [Google Scholar]
  32. Severson R. K., Nomura A. M., Grove J. S., Stemmermann G. N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989 Apr 1;49(7):1857–1860. [PubMed] [Google Scholar]
  33. Stearns M. E., Wang M. Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 1993 Feb 15;53(4):878–883. [PubMed] [Google Scholar]
  34. Tsuchiya Y., Sato H., Endo Y., Okada Y., Mai M., Sasaki T., Seiki M. Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res. 1993 Mar 15;53(6):1397–1402. [PubMed] [Google Scholar]
  35. de Veas R. G., Schweigerer L., Medina M. A. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in paediatric tumour cells. Effects of tumour cell proliferation modulators on gelatinolytic activity. J Cancer Res Clin Oncol. 1995;121(5):275–278. doi: 10.1007/BF01209593. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES